Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa SCHEMBL29352376 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL30176814 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL196981 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL34003 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL29013197 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL259452 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL5929436 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL5370162 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL11452341 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| US-9833618-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2017-12-05 | — | — | US | disclosed |
| US-20140350041-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2014-11-27 | — | — | US | disclosed |
| US-8788041-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110029030-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2011-02-03 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060206149-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-09-14 | — | — | US | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |